OVA (250-264)

OVA (250-264) (OVAvac) (OVAp) is an antigen peptide that can be from ovalbumin (OVA) presented by the class I MHC molecule, H-2Kb. OVA (250-264) combined withαMSLN (anti-MSLN antibody) significantly induces antigen-specific CD8+ T cell generation and infiltration for enhancing antitumor efficacy in orthotopic pancreatic cancer mice model. OVA (250-264) can be used for neoantigen vaccine development in pancreatic cancer immunotherapy research[1].

Product Specifications

CAS Number

[355012-70-3]

Product Name Alternative

OVAp

UNSPSC

12352209

Target

MHC

Related Pathways

Immunology/Inflammation

Field of Research

Cancer

Purity

98.14

Smiles

O=C(NCC(N[C@@H](CC(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CO)C(N[C@@H]([C@@H](C)CC)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC(N)=O)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCCN)C(N[C@@H](CC(C)C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CO)N

Molecular Formula

C77H126N18O26

Molecular Weight

1719.93

References & Citations

[1]Cai Z, et al. Targeting Mesothelin Enhances Personalized Neoantigen Vaccine Induced Antitumor Immune Response in Orthotopic Pancreatic Cancer Mouse Models. Adv Sci (Weinh) . 2025 Mar;12 (12) :e2407976.